Hypercholesterolemia - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 214 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypercholesterolemia - Pipeline Review, H2 2016, provides an overview of the Hypercholesterolemia (Metabolic Disorders) pipeline landscape.

Hypercholesterolemia arises due to high levels of cholesterol in the blood. These abnormal levels may lead to various diseases especially cardiovascular diseases. Cholesterol deposit in the arteries and may cause the narrowing of blood vessels hence restricting the blood flow. The predisposing factors for hypercholesterolemia include various diseases such as diabetes mellitus, renal diseases, obesity etc. The other factors involved are heredity, certain drugs, sedentary lifestyle, smoking, alcoholism, stress and high fat diet. The symptoms for hypercholesterolemia include blocked arteries, leg pain, chest pain and cholesterol deposits. The disease can be controlled by lifestyle changes, dietary changes, and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypercholesterolemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 13, 5, 1, 17, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively.Hypercholesterolemia.

Hypercholesterolemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypercholesterolemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypercholesterolemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypercholesterolemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypercholesterolemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypercholesterolemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Hypercholesterolemia Overview 9
Therapeutics Development 10
Pipeline Products for Hypercholesterolemia - Overview 10
Pipeline Products for Hypercholesterolemia - Comparative Analysis 11
Hypercholesterolemia - Therapeutics under Development by Companies 12
Hypercholesterolemia - Therapeutics under Investigation by Universities/Institutes 15
Hypercholesterolemia - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Hypercholesterolemia - Products under Development by Companies 20
Hypercholesterolemia - Products under Investigation by Universities/Institutes 24
Hypercholesterolemia - Companies Involved in Therapeutics Development 25
3SBio Inc 25
AFFiRiS AG 26
Akcea Therapeutics Inc 27
Alvogen Korea Co Ltd 28
ARMO Biosciences Inc 29
AstraZeneca Plc 30
BioLingus AG 31
Catabasis Pharmaceuticals Inc 32
Chong Kun Dang Pharmaceutical Corp 33
CymaBay Therapeutics Inc 34
Daewon Pharm Co Ltd 35
Dicerna Pharmaceuticals Inc 36
Dybly AG 37
Esperion Therapeutics Inc 38
Gemphire Therapeutics Inc 39
Golden Biotechnology Corp 40
Hanmi Pharmaceuticals Co Ltd 41
Immune Response BioPharma Inc 42
Johnson & Johnson 43
Kadmon Corp LLC 44
Kyorin Pharmaceutical Co Ltd 45
Leading BioSciences Inc 46
LipimetiX Development Inc 47
Lotus Pharmaceutical Co Ltd 48
Merck & Co Inc 49
Pfizer Inc 50
Planet Biotechnology Inc 51
Progenra Inc 52
Regeneron Pharmaceuticals Inc 53
RegenxBio Inc 54
Serometrix LLC 55
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd 56
Solvotrin Therapeutics Ltd 57
The Medicines Company 58
Thetis Pharmaceuticals LLC 59
Viking Therapeutics Inc 60
Zhejiang Hisun Pharmaceutical Co Ltd 61
Hypercholesterolemia - Therapeutics Assessment 62
Assessment by Monotherapy Products 62
Assessment by Combination Products 63
Assessment by Target 64
Assessment by Mechanism of Action 67
Assessment by Route of Administration 70
Assessment by Molecule Type 72
Drug Profiles 74
(aspirin + lisinopril + lovastatin) - Drug Profile 74
(atorvastatin calcium + ezetimibe) - Drug Profile 75
(atorvastatin calcium + ezetimibe) - Drug Profile 76
(atorvastatin calcium + TP-452) - Drug Profile 77
(bempedoic acid + ezetimibe) - Drug Profile 78
(candesartan cilexetil + rosuvastatin calcium) - Drug Profile 79
(ezetimibe + rosuvastatin calcium) - Drug Profile 80
AEM-28 - Drug Profile 81
AEM-2802 - Drug Profile 83
AEM-2814 - Drug Profile 84
alirocumab - Drug Profile 85
AM-0010 - Drug Profile 96
anacetrapib - Drug Profile 99
Antibodies for Metabolic Disorders - Drug Profile 101
Antisense Oligonucleotide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 102
Antisense Oligonucleotides to Inhibit ApoB100 for Familial Hypercholesterolemia - Drug Profile 103
antroquinonol - Drug Profile 104
ATH-04 - Drug Profile 106
ATH-06 - Drug Profile 107
bempedoic acid - Drug Profile 108
BSN-272 - Drug Profile 118
CAT-2000 Series - Drug Profile 119
CAT-2003 - Drug Profile 120
colestilan chloride - Drug Profile 123
D-4F - Drug Profile 124
DCRPCSK-9 - Drug Profile 125
Drugs for Hypercholesterolemia - Drug Profile 126
Drugs to Inhibit Sortilin for Hypercholesterolemia - Drug Profile 127
DW-0929 - Drug Profile 128
DW-3102 - Drug Profile 129
DYB-186 - Drug Profile 130
EP-80317 - Drug Profile 131
evinacumab - Drug Profile 132
gemcabene calcium - Drug Profile 134
Gene Therapy to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 136
HCP-1305 - Drug Profile 137
HGP-0816 - Drug Profile 138
HS-25 - Drug Profile 139
inclisiran - Drug Profile 140
IONIS-ANGPTL3LRx - Drug Profile 144
IR-1002 - Drug Profile 145
KD-026 - Drug Profile 146
MBX-8025 - Drug Profile 147
MGL-3196 - Drug Profile 150
MGL-3745 - Drug Profile 152
MN-002 - Drug Profile 153
Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 154
Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 155
PF-06446846 - Drug Profile 156
Recombinant Protein to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 157
RGX-501 - Drug Profile 158
rosuvastatin calcium - Drug Profile 160
Small Molecule for Hypercholesterolemia - Drug Profile 161
Small Molecule to Inhibit Endothelial Lipase for Hypercholesterolemia - Drug Profile 162
Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 163
Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 164
Small Molecules to Inhibit IDOL for Hypercholesterolemia - Drug Profile 165
Small Molecules to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 166
Small Molecules to Target O2 Radical and HMGCR for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile 167
ST-0702 - Drug Profile 169
SX-PCK9 - Drug Profile 170
Synthetic Peptide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 171
Vaccine to Target PCSK9 for Hypercholesterolemia - Drug Profile 172
VK-2809 - Drug Profile 173
volanesorsen sodium - Drug Profile 176
Hypercholesterolemia - Dormant Projects 182
Hypercholesterolemia - Discontinued Products 189
Hypercholesterolemia - Product Development Milestones 191
Featured News & Press Releases 191
Appendix 208
Methodology 208
Coverage 208
Secondary Research 208
Primary Research 208
Expert Panel Validation 208
Contact Us 208
Disclaimer 209

List of Tables

Number of Products under Development for Hypercholesterolemia, H2 2016 15
Number of Products under Development for Hypercholesterolemia - Comparative Analysis, H2 2016 16
Number of Products under Development by Companies, H2 2016 17
Number of Products under Development by Companies, H2 2016 (Contd..1) 18
Number of Products under Development by Companies, H2 2016 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2016 20
Comparative Analysis by Late Stage Development, H2 2016 21
Comparative Analysis by Clinical Stage Development, H2 2016 22
Comparative Analysis by Early Stage Development, H2 2016 23
Comparative Analysis by Unknown Stage Development, H2 2016 24
Products under Development by Companies, H2 2016 25
Products under Development by Companies, H2 2016 (Contd..1) 26
Products under Development by Companies, H2 2016 (Contd..2) 27
Products under Development by Companies, H2 2016 (Contd..3) 28
Products under Investigation by Universities/Institutes, H2 2016 29
Hypercholesterolemia - Pipeline by 3SBio Inc, H2 2016 30
Hypercholesterolemia - Pipeline by AFFiRiS AG, H2 2016 31
Hypercholesterolemia - Pipeline by Akcea Therapeutics Inc, H2 2016 32
Hypercholesterolemia - Pipeline by Alvogen Korea Co Ltd, H2 2016 33
Hypercholesterolemia - Pipeline by ARMO Biosciences Inc, H2 2016 34
Hypercholesterolemia - Pipeline by AstraZeneca Plc, H2 2016 35
Hypercholesterolemia - Pipeline by BioLingus AG, H2 2016 36
Hypercholesterolemia - Pipeline by Catabasis Pharmaceuticals Inc, H2 2016 37
Hypercholesterolemia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016 38
Hypercholesterolemia - Pipeline by CymaBay Therapeutics Inc, H2 2016 39
Hypercholesterolemia - Pipeline by Daewon Pharm Co Ltd, H2 2016 40
Hypercholesterolemia - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016 41
Hypercholesterolemia - Pipeline by Dybly AG, H2 2016 42
Hypercholesterolemia - Pipeline by Esperion Therapeutics Inc, H2 2016 43
Hypercholesterolemia - Pipeline by Gemphire Therapeutics Inc, H2 2016 44
Hypercholesterolemia - Pipeline by Golden Biotechnology Corp, H2 2016 45
Hypercholesterolemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 46
Hypercholesterolemia - Pipeline by Immune Response BioPharma Inc, H2 2016 47
Hypercholesterolemia - Pipeline by Johnson & Johnson, H2 2016 48
Hypercholesterolemia - Pipeline by Kadmon Corp LLC, H2 2016 49
Hypercholesterolemia - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016 50
Hypercholesterolemia - Pipeline by Leading BioSciences Inc, H2 2016 51
Hypercholesterolemia - Pipeline by LipimetiX Development Inc, H2 2016 52
Hypercholesterolemia - Pipeline by Lotus Pharmaceutical Co Ltd, H2 2016 53
Hypercholesterolemia - Pipeline by Merck & Co Inc, H2 2016 54
Hypercholesterolemia - Pipeline by Pfizer Inc, H2 2016 55
Hypercholesterolemia - Pipeline by Planet Biotechnology Inc, H2 2016 56
Hypercholesterolemia - Pipeline by Progenra Inc, H2 2016 57
Hypercholesterolemia - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 58
Hypercholesterolemia - Pipeline by RegenxBio Inc, H2 2016 59
Hypercholesterolemia - Pipeline by Serometrix LLC, H2 2016 60
Hypercholesterolemia - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2016 61
Hypercholesterolemia - Pipeline by Solvotrin Therapeutics Ltd, H2 2016 62
Hypercholesterolemia - Pipeline by The Medicines Company, H2 2016 63
Hypercholesterolemia - Pipeline by Thetis Pharmaceuticals LLC, H2 2016 64
Hypercholesterolemia - Pipeline by Viking Therapeutics Inc, H2 2016 65
Hypercholesterolemia - Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2016 66
Assessment by Monotherapy Products, H2 2016 67
Assessment by Combination Products, H2 2016 68
Number of Products by Stage and Target, H2 2016 70
Number of Products by Stage and Mechanism of Action, H2 2016 73
Number of Products by Stage and Route of Administration, H2 2016 76
Number of Products by Stage and Molecule Type, H2 2016 78
Hypercholesterolemia - Dormant Projects, H2 2016 187
Hypercholesterolemia - Dormant Projects (Contd..1), H2 2016 188
Hypercholesterolemia - Dormant Projects (Contd..2), H2 2016 189
Hypercholesterolemia - Dormant Projects (Contd..3), H2 2016 190
Hypercholesterolemia - Dormant Projects (Contd..4), H2 2016 191
Hypercholesterolemia - Dormant Projects (Contd..5), H2 2016 192
Hypercholesterolemia - Dormant Projects (Contd..6), H2 2016 193
Hypercholesterolemia - Discontinued Products, H2 2016 194
Hypercholesterolemia - Discontinued Products (Contd..1), H2 2016 195